Marie Elizabeth Manley, LMSW, CASAC | |
16204 Tuskegee Airmen Way, Jamaica, NY 11433-1608 | |
(718) 291-4844 | |
(718) 291-4511 |
Full Name | Marie Elizabeth Manley |
---|---|
Gender | Female |
Speciality | Social Worker |
Location | 16204 Tuskegee Airmen Way, Jamaica, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003336074 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 18017 (New York) | Secondary |
104100000X | Social Worker | 094736-1 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Marie Elizabeth Manley, LMSW, CASAC 16204 Tuskegee Airmen Way, Jamaica, NY 11433-1608 Ph: (718) 291-4844 | Marie Elizabeth Manley, LMSW, CASAC 16204 Tuskegee Airmen Way, Jamaica, NY 11433-1608 Ph: (718) 291-4844 |
News Archive
Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.
A new study by researchers from the London School of Hygiene and Tropical Medicine, Cambridge University and the Karolinska Institute in Sweden has found that even light or moderate intensity physical activity, such as walking or cycling, can substantially reduced the risk of early death.
A recent review found that male doctors in the United Kingdom receive an average £67,788 in basic pay while female doctors get paid £57,569 a year. The gap is of £10,219 or 15%. Overall the NHS has a gender pay gap of 23%.
Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
› Verified 8 days ago